Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
End-stage renal disease (ESRD) patients often develop cardiovascular complications, and
cardiovascular disease is the leading cause of death in this population. Ranolazine's ability
to treat angina without reducing heart rate or blood pressure makes it an important option
for ESRD patients. The hemodialysis clearance of ranolazine is unknown. A single-dose
pharmacokinetic study is needed to characterize ranolazine and its metabolites in ESRD
patients on and off hemodialysis. Results of the proposed study will provide initial dosing
estimates for a follow-up, multiple-dose pharmacokinetic study in this population.